We are live on ! Find out more
IGC icon

IGC Pharma
IGC

21 hedge funds and large institutions have $694K invested in IGC Pharma in 2020 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more call options, than puts

Call options by funds: $6K | Put options by funds: $1K

0.4% less ownership

Funds ownership: 4.03% → 3.63% (-0.4%)

19% less funds holding

Funds holding: 26 → 21 (-5)

31% less capital invested

Capital invested by funds: $1M → $694K (-$308K)

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

Holders
21
Holders Change
-5
Holders Change %
-19.23%
% of All Funds
0.46%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
1
Reduced
3
Closed
6
Calls
$6K
Puts
$1K
Net Calls
+$5K
Net Calls Change
+$8K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$33.4K
2
Wells Fargo
Wells Fargo
California
+$126
3
GSWM
Golden State Wealth Management
California
+$125
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$68

Top Sellers

Rank Fund Capital Flow
1
Creative Planning
Creative Planning
Kansas
-$57K
2
Citadel Advisors
Citadel Advisors
Florida
-$9K
3
UBS Group
UBS Group
Switzerland
-$6.92K
4
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
-$6K
5
Group One Trading
Group One Trading
Illinois
-$1.79K

IGC Hedge Fund Activity: Q1 2020 in Review

21 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q1 2020, worth a combined $694K — down 31% from $1M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of IGC and 4 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 1 added.

The largest buyer was BlackRock, adding an estimated $33.4K. The largest seller was Creative Planning, exiting entirely with an estimated $57K sold.

  • 21 institutional investors held IGC Pharma (IGC) as of Q1 2020, down from 26 in Q4 2019.
  • Funds reported $694K of IGC Pharma stock for Q1 2020, down 31% quarter-over-quarter.
  • 4 funds opened new IGC Pharma positions in Q1 2020 and 6 closed out, a net change of -2 holders.
  • The largest IGC Pharma buyer in Q1 2020 was BlackRock, an estimated $33.4K added.
  • The largest IGC Pharma seller in Q1 2020 was Creative Planning, an estimated $57K sold.

Based on aggregated 13F filings for Q1 2020.